Prescient Healthcare Group, a leading biopharma product and portfolio strategy firm, has announced the appointment of Dr. Luke Solon and Debbie Allman to its Board of Directors. Solon, who leads Prescient's global medical practice, brings over 20 years of healthcare, consulting, and pharmaceutical industry experience, including roles at McKinsey & Company, AstraZeneca, and KPMG. His expertise spans multiple therapy areas and the entire asset lifecycle, emphasizing a clinical lens in medical affairs and commercial engagements. Debbie Allman, Head of Prescient's Global Commercial practice, contributes her extensive commercial strategy background, gained from AstraZeneca and Strategic North, a consultancy she co-founded that was later acquired by Prescient. Allman's focus lies in driving growth in the U.S. market and ensuring customer-centric strategic decision-making in brand planning and new product development.
Dr. Debasish Talukdar, CEO of Prescient, and Dr. Nicholas Edwards, Chairman, expressed enthusiasm for the appointment, highlighting the invaluable industry expertise and independent perspectives that Solon and Allman bring to the Board. With a diverse team of over 500 professionals across global hubs, Prescient continues to serve as a strategic partner to biopharmaceutical companies worldwide, leveraging its scientific knowledge and market insights to unlock innovation and improve lives globally.
